Prevention & care

Lung cancer: cell types, risk beyond smoking, staging, tumor tests, and screening disagreements

8 sources · Latest source check 2026-10-08 UTC

On this page

Lung cancer begins in lung tissue or airways. The main groups are non-small cell and small cell lung cancer. These names describe cell types, not tumor size. Non-small cell cancer includes several subtypes with different biology; a general lung-cancer label cannot settle treatment or prognosis.[1]

The main tissue categories

The main tissue categories
Category	What the name means
Non-small cell	A broader group, including the subtypes below.[1]
Adenocarcinoma	Starts in glandular cells, including cells associated with the air sacs.[1]
Squamous / large cell	Other non-small cell appearances and origins.[1]
Small cell	A distinct, often fast-growing group.[2]

Smoking is a major cause, but not the only cause

CDC identifies tobacco smoke, secondhand smoke, radon and workplace exposures as important lung-cancer risks. Radon can cause lung cancer in people who have never smoked. It is an invisible, odorless gas that can accumulate indoors. A diagnosis should not be reduced to blame or used to infer a person’s smoking history.[3]

Quitting and exposure reduction still matter

CDC describes lower lung-cancer risk after quitting smoking. A remaining risk is not a reason to conclude that quitting was pointless. Workplace and indoor exposures also deserve attention; an absence of symptoms cannot measure radon or establish the safety of an occupational exposure.[3]

A nutrient in food and a concentrated supplement are different exposures

CDC describes increased lung-cancer risk with beta-carotene supplements, especially in people who smoke heavily. It distinguishes this from eating foods containing beta-carotene. An antioxidant mechanism does not establish that a supplement prevents lung cancer.[3]

A persistent change needs assessment outside screening rules

NHS lists a persistent cough, breathlessness, coughing blood, recurring chest infections and unexplained weight loss among possible symptoms. They can have other causes and early cancer can be symptom-free. Coughing blood warrants prompt assessment; severe breathing difficulty needs emergency help according to local services. A symptom list cannot diagnose cancer.[4]

Images and tissue answer different questions

NHS describes CT, bronchoscopy and other tests in specialist investigation. Bronchoscopy uses a flexible camera to inspect airways; tissue sampling can establish cell type. Further imaging and laboratory or genetic tests address extent and treatment questions. A suspicious nodule is not automatically cancer, and not everyone needs every procedure.[5]

Cell type and extent must stay separate

Non-small cell cancer commonly uses TNM-based stage categories describing extent. Small cell cancer is commonly discussed as limited or extensive stage, reflecting how far it has spread. Neither “small cell” nor “non-small cell” is itself a stage or a measurement of the tumor.[1][2]

Gene changes can inform treatment without guaranteeing response

NCI identifies cancer gene changes such as EGFR or ALK alterations as relevant to non-small cell treatment options and prognosis. Testing a tumor feature is different from proving a particular medicine will work. A result must be interpreted with the cancer type, extent and other findings.[1]

The 2021 USPSTF recommendation retains a quit-year criterion

USPSTF recommends annual low-dose CT for its selected population aged 50 to 80 with at least 20 pack-years of smoking who currently smoke or quit within 15 years. It includes stopping criteria tied to health and willingness or ability to undergo curative lung surgery. A pack-year combines smoking intensity and duration; it is not simply a count of calendar years.[7]

The 2023 ACS update makes a different eligibility judgment

The ACS guideline recommends annual low-dose CT for asymptomatic people aged 50 to 80 with at least 20 pack-years who currently or formerly smoked. Years since quitting are no longer an entry or stopping criterion. Serious illness limiting life expectancy and treatment suitability still matter; the recommendation does not extend routine screening to everyone who has never smoked.[8]

ACS used reviews, additional evidence about continuing risk after quitting, and modeling alongside earlier trial evidence. It rated overall evidence moderate and made a strong recommendation. Recommendation strength is an organization’s judgment about benefits and harms; the Atlas has not independently regraded it or reconciled every local coverage rule.[8]

Screening finds nodules as well as cancers

USPSTF weighs mortality benefit against false positives, further investigations, overdiagnosis, incidental findings and radiation exposure. An abnormal scan is not a cancer diagnosis. A screening chest CT and a diagnostic investigation prompted by symptoms have different purposes, even when both involve imaging.[7]

Care may combine local and systemic treatments

NHS describes surgery, radiation, chemotherapy, targeted medicines and immunotherapy in appropriate settings. Cell type, spread, genetic findings, general health and preferences influence selection. Medicines before surgery, after surgery or for advanced disease have different aims. Treatment eligibility cannot be inferred from the phrase “lung cancer” alone.[6]

Questions can include the purpose of treatment, likely absolute benefit, effects on breathing and daily function, adverse effects and follow-up. Symptom support and palliative care address comfort and function; control of advanced disease is not the same outcome as cure.[6]

Evidence & uncertainty

Screening eligibility differs between major US organizations, including how they handle years since quitting smoking. Both frameworks concern selected people without symptoms. A disagreement over eligibility is not evidence that every person benefits from CT screening or that new symptoms should wait.[7][8]

Selected-source overview · Independent review pending

Published questions

Does small cell lung cancer mean a physically small tumor?

Selected-source overview · Independent review pending. Read the evidence context.

The label refers to cell type, not tumor size.[2]

Evidence behind this answer

Small Cell Lung Cancer Treatment (PDQ), Patient Version
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Cell-type meaning and limited versus extensive disease